Trials / Terminated
TerminatedNCT02626754
A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- vghtpe user · Other Government
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-national, phase II, single arm study to explore the safety/efficacy and potential biomarkers on sunitinib 2/1 schedule for Asian patients with advanced renal cell carcinoma.
Detailed description
Sunitinib 50mg daily on 4/2 dose schedule has been established as standard of care (SOC) for advanced renal cell carcinoma (RCC). However, Asian patients in real world experienced grade III/IV adverse events much more than expected. This multi-national, phase II, single arm study is going to explore more on the safety/efficacy and relevant biomarkers on sunitinib 2/1 dose schedule in Asian people with advanced RCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunitinib malate | Sunitinib 50mg will be given for 2 consecutive weeks then followed by one week of rest. |
Timeline
- Start date
- 2015-08-12
- Primary completion
- 2018-01-02
- Completion
- 2018-01-02
- First posted
- 2015-12-10
- Last updated
- 2018-06-26
Locations
7 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT02626754. Inclusion in this directory is not an endorsement.